Restricted accessResearch articleFirst published online 1997-10
Attuali Prospettive Terapeutiche Nel Trattamento Delle Complicanze Emorragiche Nei Pazienti Uremici in Trattamento Dialitico: Ruolo Della Terapia Con Estrogeni Coniugati e Loro Effetti Sulle Interazioni Piastrine-Endotelio Mediati Da Riespressione Delle Integrine Di Superficie Sulla Membrana Piastrinica
WatsonA.J., GimenezL.F.The bleeding diathesis of uremia. Semin Dial1991; 4: 86–93.
2.
Di MinnoG., MartinezJ., McKeanM.L., DeLa RosaJ., BurkeJ.F., MurphyS.Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med1985; 79: 552–9.
3.
LivioE., BenigniA., RemuzziG.Coagulation abnormalities in uremia. Semin Nephrol1985; 5: 82–90.
4.
EscolarG., CasesA., BastidaE.Uraemic platelets have a functional defect affecting the interaction of von Willebrand Factor with glycoprotein IIb/IIIa:Blood1990; 76: 1336–40.
5.
SloandE.M., SloandJ.A., ProdouzK.Reduction of platelet glycoprotein Ib in uremia. Br J Haematol1991; 77: 375–81.
6.
LianiM., SalvatiF., GolatoM., TrescaE.Platelet glycoproteins GPIb and GPIIb/IIIa abnormalities in uremia. Nephron1996; 72: 716.
7.
GawazM.P., DobosG., SpathM.Impaired function of platelet membrane glycoprotein IIb/IIIa in end stage renal disease. J Am Soc Nephrol1994; 5: 36–46.
8.
BenigniA., BoccardoP., GalbuseraM.Reversible activation defect of the platelet glycoprotein IIb/IIIa complex in patients with uremia. Am J Kidney Dis1993; 22: 668–76.
9.
The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl. J Med1994; 330: 956–61.
10.
TchengJ.E.Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT-II, RESTORE and EPILOG trials into perspective. Am J Cardiol1996; 78(Suppl 3A): 35–40.
11.
The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. The CAPTURE Study. Lancet1997; 349: 1429–35.
12.
The Impact II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet1997; 349: 1422–8.
13.
KereiakesD.J., RunyonJ.P., KleimanN.S.Differential dose-response to oral xemilofiban after antecedent intra venous abciximab. Administration for complex coronary intervention. Circulation1996; 94: 906–10.
14.
VerheugtF.W.In search of a superaspirin for the heart. Lancet1997; 349: 1409–10.
15.
LianiM., SalvatiF., TrescaE.Arteriovenous fistula obstruction and expression of platelet receptors for von Willebrand Factor and for fibrinogen (glycoproteins GPIb and GPIIb/IIIa) in hemodialysis patients. Int J Artif Organs1996; 19: 451–4.
16.
LianiM., SalvatiF., TrescaE.Bleeding diathesis in uremic patients treated with peritoneal dialysis: role of glycoproteins GPIb and GPIIb/IIIa abnormalities. Nephron1996; 74: 234.
17.
SloandJ.A.Long term therapy for uremic bleeding. Int J Artif Organs1996; 19: 439–40.
18.
LianiM., SalvatiF., NubileG., TrescaE., VelussiC., MidrioM.Von Willebrand Factor and rise in ristocetin co-factor with erythropoietin. Lancet1993; 341: 1221.
19.
JansonP.A., JubelilerS.J., WeinstenM.S., DeykinD.Treatment of bleeding tendency in uremia with cryoprecipitate. N Engl J Med1980; 303: 1318–22.
20.
SloandE.M., KesslerC.M., SloandJ.A.DDAVP corrects the platelet dysfunction produced by cardiopulmonary by-pass, hemodialysis, and prolonged storage: Re-expression of GPIb on the platelet membrane.New York: Plenum Press, Desmopressin in Bleeding Dis1993; 147–54.
21.
ViganóG., GaspariF., LocatelliM., PusineriF., BonatiM., RemuzziG.Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int1988; 34: 853–8.
22.
ZoyaC., NorisM., CornaD.L-Arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia. Lab Invest1991; 65: 479–83.
23.
HoffmannJJML, JanssenW.C.M.Interactions between thrombolytic agents and platelets: effects of plasmine on platelet glycoproteins Ib and IIb/IIIa. Thrombosis Research1992; 67: 711–9.
24.
LianiM., TrescaE., NubileG., SalvatiF., TrollietP., CahenR.Effects of dietary manipulation with Fish-Oil on platelet receptors for von Willebrand Factor and Fibrinogen in Patients with end-stage renal failure. Nephron1995; 69: 170.
25.
SalvatiF., LianiM., GolatoM.Long term therapy for uremic bleeding: effects of conjugate estrogens on the expression of platelet surface receptors for von Willebrand Factor and fibrinogen (GPIb and GPIIb/IIIa glycoproteins). Int J Artif Organs1997; 20: 184–5.
